After 43+ years working for one investment research company or another, I finally retired. So now, I’m completely independent. And for the first time on Seeking Alpha, I won’t be working based on anybody else’s product agenda. I have only one goal now… to give you the best actionable investment insights I can.I have long specialized in rules/factor-based equity investing strategies. But I’m different from others who share such backgrounds. I don’t serve the numbers. Instead, the numbers serve me… to inspire ...

Editas Medicine (NasdaqGS:EDIT) Conference October 14, 2025 07:00 AM ET Speaker0Hello, everyone. My name is Mitchell Kapoor. I'm a senior biotech analyst at H. C. Wainwright.It's my pleasure to welcome you to the genetic medicines conference. Today, I have Editas with me. I have this I have the pleasure of welcoming Gilmore O'Neill, the CEO, and Amy Bresen, the CFO. Thank you both for joining us today.Speaker1It's great to be with you, Mitch. Thanks for the time.Speaker2Thanks, Ryan. JustSpeaker0to kick us ...

Key Points - Several biotech stocks experienced notable after-hours gains on October 9, driven by new data and corporate developments [1] Company Summaries Palisade Bio Inc. (PALI) - Shares traded at $2.26 in after-hours, reflecting a 7.62% gain from the prior close of $2.10, which was up 5% on the day [1] - The company cancelled its special meeting of stockholders due to lack of quorum, withdrawing all proposals from consideration [2] Healthcare Triangle Inc. (HCTI) - Shares traded at $2.88 in after-hours, up 4.35% from the regular session close of $2.76, which was down 17.86% [3] - The company signed a non-binding Letter of Intent to acquire Teyame.AI, projected to generate $34 million in revenue for fiscal year 2025 [4] Nutriband Inc. (NTRB) - Shares traded at $8.25 in after-hours, up 4.30% from the regular session close of $7.91, which was down 6.94% [5] - The company filed a provisional patent application with the USPTO to strengthen its intellectual property for its AVERSA abuse deterrent transdermal [5] Karyopharm Therapeutics Inc. (KPTI) - Shares traded at $6.08 in after-hours, up 4.46% from the regular session close of $5.82, which had declined 1.36% [6] - The company announced financing transactions expected to provide $100 million in financial flexibility, extending its cash runway into Q2 2026 [6] Editas Medicine Inc. (EDIT) - Shares traded at $4.22 in after-hours, up 3.43% from the regular session close of $4.08, which was down 1.69% [7] - The company presented new preclinical proof-of-concept data for its therapy EDIT-401, showing a 90% LDL-C reduction in non-human primates and mice [7] CG Oncology Inc. (CGON) - Shares traded at $45.40 in after-hours, up 2.11% from the regular session close of $44.46, which gained 9.21% [8] - No official news releases or filings were issued during the day [8]

CAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class, one-time therapy to significantly reduce LDL-cholesterol (LDL-C), at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress in Seville, Spain. The Company shared results from preclinical studies demonstrating potent and durable reductions in LDL-C throug ...

Preclinical data demonstrates proof-of-concept for EDIT-401 with ≥90% mean LDL-C reduction in non-human primates and mouse modelsCAMBRIDGE, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today reported in vivo preclinical proof-of-concept data for EDIT-401, an experimental, potential best-in-class, one-time therapy to significantly reduce LDL-cholesterol (LDL-C), at the 32nd Annual European Society of Gene and Cell Therapy (ESGCT) Congress i ...

CAMBRIDGE, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene and Cell Therapy (ESGCT) Congress, to be held October 7-10, 2025, in Seville, Spain. European Society of Gene and Cell Therapy (ESGCT) CongressTitle: A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine that functi ...

Core Viewpoint - Editas Medicine reported a wider-than-expected loss in Q2 2025, with shares declining approximately 16.9% since the last earnings report, underperforming the S&P 500 [1][2]. Financial Performance - Editas reported a loss of 63 cents per share in Q2 2025, which was worse than the Zacks Consensus Estimate of a loss of 41 cents, compared to a loss of 82 cents per share in the same quarter last year [2]. - Collaboration and other R&D revenues were $3.6 million in Q2 2025, significantly up from the previous year's figure and exceeding the Zacks Consensus Estimate of $1 million, primarily due to revenue recognition from achieved deliverables [3]. - R&D expenses decreased by 70% to $16.2 million compared to $54.2 million in the prior year, attributed to lower clinical and manufacturing costs following the abandonment of the reni-cel program [4]. - General and administrative expenses were $12.9 million, down 29% year-over-year due to reduced employee-related expenses from a decreased headcount [5]. - Restructuring and impairment charges amounted to $26.1 million in Q2 2025 due to the discontinuation of the reni-cel program, with no such charges recorded in the previous year [5]. - As of June 30, 2025, Editas had cash, cash equivalents, and investments totaling $178.5 million, down from $221 million as of March 31, 2025, with expectations to fund operations into Q2 2027 [6]. Market Sentiment - Estimates for Editas have trended upward over the past month, indicating a potentially positive outlook [7]. - Editas holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [9]. Industry Comparison - Editas is part of the Zacks Medical - Biomedical and Genetics industry, where GSK has gained 3.5% over the past month, reporting revenues of $10.67 billion for the last quarter, reflecting a year-over-year increase of 7.2% [11].

Summary of Editas Medicine (EDIT) Conference Call Company Overview - Editas Medicine is transitioning to a fully in vivo CRISPR editing company, focusing on gene editing technologies that demonstrate a high probability of success in clinical translation [3][6] - The company has selected EDIT-401 as its lead asset, targeting LDLR to achieve a 90% reduction in LDL cholesterol, with plans to reach human proof of concept by 2026 [4][17] Core Technology and Differentiation - Editas differentiates itself through its unique approach to CRISPR technology, focusing on upregulating proteins with therapeutic benefits rather than merely editing genes [6][8] - The in vivo approach simplifies treatment delivery, reducing costs and complexity compared to autologous cell therapies [9][10] - The company leverages large curated genetic datasets to de-risk target selection, allowing for innovative applications of CRISPR technology [8][10] Product Development and Market Potential - EDIT-401 has shown robust preclinical efficacy, achieving a 90% reduction in LDL cholesterol across various models, including nonhuman primates and mouse models [16][24] - The treatment is positioned as a potential one-time infusion, contrasting with current therapies that require ongoing management [17][24] - The market for hyperlipidemia treatments is substantial, with opportunities in refractory heterozygous familial hypercholesterolemia and high-risk patients not meeting cholesterol targets [17][26] Economic Model and Commercial Strategy - Editas aims to create a competitive pricing model that reflects the durable effects of its treatment while maintaining value for shareholders [38][39] - The company anticipates lower manufacturing costs due to its off-the-shelf LNP technology, allowing for better margins compared to traditional cell therapies [38][40] - Preliminary discussions with payers indicate recognition of the potential transformational nature of EDIT-401, with interest in upfront use for specific patient populations [42][43] Financial Position - Editas reported a cash balance of $179 million as of Q2 2025, providing a runway into Q2 2027 to fund the development of EDIT-401 and other pipeline projects [53][54] - The company plans to announce an additional target by the end of the year, expanding its focus beyond liver and hematopoietic stem cell (HSC) targets [54][56] Future Milestones - Key upcoming milestones include the completion of GMP manufacturing, dose range finding studies, and the development of an off-target editing package, all aimed at achieving a human IND submission in 2026 [21][22] - The company is actively exploring patient recruitment sites for its Phase 1 clinical trials [21][22] Conclusion - Editas Medicine is strategically positioned in the gene editing space with a focus on innovative in vivo applications of CRISPR technology, aiming to transform the treatment landscape for hyperlipidemia while ensuring economic viability and shareholder value [3][4][17]

Financial Data and Key Metrics Changes - The company is advancing its lead development candidate, Edit 401, which has shown a 90% mean reduction in LDL cholesterol in preclinical studies, significantly outperforming current standard treatments that achieve 40% to 60% reductions [5][18]. - Edit 401 is expected to provide a one-time treatment option with a durable lifetime reduction in LDL levels, which could transform the treatment landscape for hyperlipidemia [6][19]. Business Line Data and Key Metrics Changes - Edit 401 has been selected as the lead program due to its compelling preclinical data, which supports rapid progression to human proof of concept studies expected by the end of 2026 [6][19]. - The company is also focusing on optimizing candidates for its hematopoietic stem cell (HSC) program while advancing Edit 401 [20]. Market Data and Key Metrics Changes - The market potential for Edit 401 is substantial, with the U.S. healthcare system projected to spend over $300 billion on atherosclerotic cardiovascular disease by 2035 [6]. - Hyperlipidemia affects over 70 million patients in the U.S., indicating a significant patient population that could benefit from Edit 401 [7]. Company Strategy and Development Direction - The company aims to be a leader in in vivo gene editing by developing CRISPR-based medicines that are best in class or first in class therapeutics [4]. - The strategy involves a differentiated approach using functional regulation rather than knockdown strategies, allowing the company to target areas others cannot [10]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Edit 401's potential to deliver meaningful benefits across multiple segments of the hyperlipidemia population, supported by strong preclinical data [16][19]. - The company remains committed to advancing its pipeline and optimizing resources for its lead program while exploring other therapeutic areas [20]. Other Important Information - Edit 401 utilizes a proprietary CRISPR-Cas9 enzyme and dual guide RNAs, demonstrating a robust safety profile with no adverse effects observed in preclinical studies [14][108]. - The company is conducting long-term durability studies to assess the lasting effects of Edit 401 and its potential for redosing if necessary [117][119]. Q&A Session Summary Question: What patient populations will be targeted for Edit 401 testing? - Management indicated that heterozygous familial hypercholesterolemia and other refractory segments would be significant considerations for initial testing [22][23]. Question: Is there evidence that a 90% LDL reduction would lower cardiovascular risk? - Management confirmed that clinical trials indicate a 20% risk reduction for every 40 mg/dL lowering of LDL, supporting the potential for greater risk reduction with Edit 401 [32][33]. Question: How do you anticipate LDL reduction in mice translating to humans? - Management expressed confidence in the translatability of results from non-human primates to humans, projecting that a human dose will be below 1 mg/kg [35]. Question: What is the minimal effective LDL reduction needed for a viable product? - Management noted that reductions of 60% have shown benefits, but they are confident in the transformational levels of reduction observed with Edit 401 [54]. Question: What are the long-term safety considerations for Edit 401? - Management highlighted that the Icelandic cohort provides genetic validation for safety, and no adverse events have been observed in preclinical studies [47][88]. Question: Will there be a need for redosing in the future? - Management indicated that while they are currently seeing durability out to 12 weeks, they believe there is room for redosing if needed [117][119].

Financial Data and Key Metrics Changes - The company is advancing its lead development candidate, Edit 401, which has shown a 90% mean reduction in LDL cholesterol in preclinical studies, significantly outperforming current standard treatments that achieve 40% to 60% reductions [4][18]. - Edit 401 is positioned as a one-time treatment with the potential for lifelong LDL reduction and associated cardiovascular risk reduction, indicating a favorable business model aligned with typical biopharma margins [5][18]. Business Line Data and Key Metrics Changes - Edit 401 has been selected as the lead program due to its compelling preclinical data, which supports rapid progression to human proof of concept studies expected by the end of 2026 [5][19]. - The company is also focusing on optimizing candidates for its hematopoietic stem cell (HSC) program while advancing Edit 401 [19][20]. Market Data and Key Metrics Changes - The market potential for Edit 401 is substantial, with projections indicating that atherosclerotic cardiovascular disease will impose over $300 billion in national expenditures by 2035 in the U.S. alone [5]. - Hyperlipidemia affects over 70 million patients in the U.S., highlighting a significant patient population that could benefit from Edit 401 [6]. Company Strategy and Development Direction - The company aims to be a leader in in vivo gene editing by developing CRISPR-based medicines that are best in class or first in class therapeutics [3]. - The strategy involves a differentiated approach focusing on functional upregulation of gene expression rather than knockdown strategies, allowing the company to target areas others cannot [10]. Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Edit 401's potential to deliver meaningful benefits across multiple segments of the hyperlipidemia population, emphasizing the need for effective treatments in refractory patient segments [7][19]. - The company remains committed to advancing its pipeline and optimizing resources for its lead program while exploring other therapeutic areas [19][20]. Other Important Information - Edit 401 utilizes a proprietary CRISPR-Cas9 enzyme and dual guide RNAs, demonstrating a six-fold mean increase in LDLR protein levels, which is crucial for its efficacy [12][13]. - The company has established a strategic partnership with Genevant for LNP delivery, which has shown good tolerability in preclinical studies [13][100]. Q&A Session Summary Question: What patient populations will be targeted for Edit 401 testing? - The company plans to consider segments such as heterozygous familial hypercholesterolemia and other refractory patient populations, with final selections depending on regulatory discussions [24]. Question: Is there evidence that 90% LDL reduction leads to lower cardiovascular risk? - Management indicated that clinical trials show a 20% risk reduction for every 40 mg/dL lowering of LDL-C, with lower levels associated with even greater risk reductions [32][34]. Question: How will LDL reduction in mice translate to humans? - The company is optimistic about translatability, having observed consistent 90% reductions in both non-human primates and mice, projecting that human doses will be below 1 mg/kg [36]. Question: What is the expected market positioning for Edit 401? - Edit 401 is expected to serve severe patient populations, particularly those who do not achieve LDL targets with existing therapies, due to its significant efficacy and compliance advantages [42][44]. Question: What are the safety profiles observed in preclinical studies? - The company reported no thrombocytopenia and transient liver enzyme elevations that resolved within a week, indicating a favorable safety profile [110]. Question: Will there be a need for redosing in the future? - While the company has shown durability of LDL reduction for at least 12 weeks, they believe there is room for redosing if necessary [118][120]. Question: What are the expectations for future clinical trial requirements? - The company anticipates that different patient segments may have varying requirements determined by regulators, but expects to require a small population to detect the biological effect size in human studies [129].